

# 1 The effect of the presence of biosurfactant on the permeation of pharmaceutical 2 compounds through silicone membrane

3 Lorena Rodríguez-López<sup>1,2</sup>, Dina S. Shokry<sup>3</sup>, Jose M. Cruz<sup>2</sup>, Ana B. Moldes<sup>2</sup> and Laura J. Waters\*<sup>1</sup>

4  
5 <sup>1</sup> School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, HD1 3DH, UK

6 <sup>2</sup> School of Industrial Engineering, University of Vigo, Campus As Lagoas-Marcosende 36310 Vigo-  
7 Pontevedra, Spain

8 <sup>3</sup> Faculty of Engineering and Science, Medway Centre for Formulation Science, University of Greenwich,  
9 Chatham, Kent ME4 4TB, UK.

10 \*Corresponding author: l.waters@hud.ac.uk

## 11 12 **Abstract**

13 The permeation of ten model drugs through silicone membrane was analysed to investigate  
14 the effect of the presence of a biosurfactant obtained from corn steep liquor. The ten selected  
15 pharmaceutical compounds were chosen to include a diverse range of physicochemical  
16 properties, such as variable hydrophobicities, pKa's, molecular masses and degrees of  
17 ionisation. When compared with compound permeation alone, the additional inclusion of  
18 biosurfactant in the donor phase altered the rate and extent of permeation. It significantly  
19 enhanced permeation for five of the compounds, whereas it decreased permeation for four of  
20 the compounds and remained approximately the same for the tenth compound. These effects  
21 were observed at both biosurfactant concentrations considered, namely 0.005 mg/mL, i.e.  
22 below the critical micellar concentration (CMC) and 0.500 mg/mL, i.e. above the CMC of the  
23 biosurfactant. Upon analysing permeation change with respect to physicochemical properties  
24 of the compounds, it was determined that compounds with a relative molecular mass below  
25 200 resulted in an increase in permeation with biosurfactant present, and those above 200  
26 resulted in a decrease in permeation with biosurfactant present. This effect was therefore  
27 attributed to the formation of a drug-biosurfactant interaction that enhanced permeation of  
28 smaller compounds, yet retarded permeation for those with a higher molecular mass. These *in*  
29 *vitro* findings can be considered an indication of potential novel formulation options that  
30 incorporate biosurfactant to create transdermal products that have bespoke permeation  
31 profiles.

32 **Keywords:** PDMS; biosurfactant; permeation; membrane; polydimethylsiloxane; flow-  
33 through diffusion.

34 **Statistical Summary:** words = 5045, tables = 4, figures = 3 (+1 supp)

35

## 36 **Introduction**

37 Biosurfactants are natural detergents composed of lipids, sugars and/or proteins [1]. They are  
38 known for being more biocompatible than their chemical homologues, such as sodium  
39 dodecyl sulphate (SDS), themselves used in pharmaceutical formulations to solubilise active  
40 ingredients and improve permeation through skin.

41 Biosurfactants display similar properties to the more well-known standard surfactants.  
42 However, they are produced by microorganisms, and composed of biomolecules, being less  
43 toxic, more biocompatible, and biodegradable than chemical surfactants [2]. Many studies  
44 have demonstrated the potential uses of biosurfactants in different fields, including  
45 environmental applications [3, 4], the food industry [5, 6] and cosmetic formulations [7, 8].  
46 However, very limited research exists regarding the application of biosurfactants in the  
47 pharmaceutical industry. Related to the applications of biosurfactants in these two last areas,  
48 some researchers have observed an antimicrobial activity of several biosurfactants against  
49 pathogenic strains [9-11]. Additionally, researchers have discovered that a biosurfactant  
50 obtained from corn steep liquor (CSL) exhibits sunscreen protective properties [12]. Corn  
51 steep liquor is a corn stream, obtained from the corn wet-milling industry, spontaneously  
52 fermented by lactic acid bacteria, which is “Generally Recognized As Safe” (GRAS) by the  
53 US Food and Drug Administration (FDA). Furthermore, the same authors have observed that  
54 it is adsorbed on hair, potentially encouraging the permeation of compounds through the skin  
55 [13, 14].

56

57 It is widely known that the permeation of a compound (both *in vitro* and *in vivo*) can be  
58 dramatically affected by the additional presence of other compounds, known as permeation  
59 enhancers [15] or retarders [16], including groups of molecules such as surfactants [17].  
60 Surfactants are compounds with surface-active properties and are known to affect the rate and  
61 extent of permeation. For this reason, surfactants are widely used in topical formulations [18].  
62 Although they have been shown to enhance permeation under certain circumstances, many  
63 studies have demonstrated that their topical use, in cosmetic or pharmaceutical products, can  
64 be a problematic issue for the patient, sometimes causing unwanted side effects such as  
65 contact dermatitis and irritation [19]. For this reason new detergents, such as biosurfactants,  
66 that avoid these issues, are currently highly desirable as one potential solution for drug  
67 delivery [20], although their effect on skin permeation is yet unknown.

68 Skin is the largest organ in the human body, generally seen as a useful barrier against the  
69 unwanted transfer of undesirable contaminants. However, dermatological pharmaceutical  
70 formulations, such as foams, creams and gels, can take advantage of the skins permeation  
71 potential for systemic delivery, often chosen because of their non-invasive nature and ease of  
72 application for the patient with anticipated growth in the market [21]. In order to study the  
73 permeation behaviour of compounds and formulations considered for transdermal delivery,  
74 human skin models are viewed as the best surrogate for clinical data [22, 23], yet present  
75 many ethical, economic and technical problems concerning availability [24]. For example,  
76 skin samples require complex storage, suffer from reproducibility as a consequence of  
77 variations in skin absorption across different body sites and can be costly studies to  
78 undertake. For this reason the majority of transdermal analysis is undertaken using animal  
79 skin, such as pig, mouse, rat, guinea pig or even snake skin [25]. However, animal tissues  
80 also have several disadvantages and challenges, with the most significant issue being the  
81 frequent lack of correlation between human and animal skin data [26]. In recent years, several  
82 *in vitro* techniques have been developed to determine topical permeation data, thus avoiding  
83 (incomparable) animal or (complex) human models [27]. One such group of alternatives is  
84 based on the use of polymer materials [28], including polydimethoxysiloxane (PDMS), as a  
85 barrier membrane for permeation that can be used in diffusion systems. PDMS represents a  
86 simple alternative option (in comparison with the systems previously discussed) overcoming  
87 many of their disadvantages such as cost, complexity and ethical considerations. Moreover,  
88 PDMS is particularly useful for studying basic permeation mechanisms, and ranking drugs  
89 and formulations through comparison of their permeation profiles [16, 29, 30]. For example,  
90 PDMS membrane has been reported to produce data displaying a good correlation with an *in*  
91 *vivo* system whereby the penetrant lipophilicity was the prime determinant of compound  
92 permeation [31].

93 Therefore, the aim of this work was to evaluate the effect of a biosurfactant extract obtained  
94 from a corn wet-milling industry stream, on the permeation of a set of model drugs, through a  
95 silicone membrane-based diffusion system. Ten compounds were selected for analysis that  
96 covered a wide range of physicochemical properties such as variations in hydrophobicity  
97 (reflected in logP values), degrees of ionisation (reflected in pKa values), molecular mass and  
98 polar surface area, along with the relative acidity/basicity of the compound. This resulted in a  
99 set of model compounds that would ultimately facilitate the analysis of a relationship  
100 between the degree of permeation and the compounds properties driving the process. The ten

101 compounds analysed in this work were: benzocaine, benzoic acid, benzotriazole, caffeine,  
102 ibuprofen, indomethacin, lidocaine, procaine, salicylic acid and tetracaine.

103 Overall, in this study, the permeation of ten compounds through PDMS was measured in the  
104 presence and absence of two concentrations of an extracted biosurfactant, i.e. above and  
105 below its critical micellar concentration (CMC), in order to establish the effect of  
106 biosurfactant presence and micelle formation in permeation studies.

## 107 **Materials and Methods**

### 108 **Materials**

109 Polydimethylsiloxane membrane (PDMS) was used as purchased (ATOS Medical, Sweden)  
110 with a standard thickness of 130  $\mu\text{m}$  and cut to size as required. Ten pharmaceutical  
111 compounds were analysed in this study namely: benzocaine (Sigma Aldrich), benzoic acid  
112 (Sigma Aldrich), benzotriazole (Sigma Aldrich), caffeine (Sigma Aldrich), ibuprofen  
113 (BASF), indomethacin (Sigma Aldrich), lidocaine (Sigma Aldrich), procaine (Sigma  
114 Aldrich), salicylic acid (Sigma Aldrich) and tetracaine (Sigma Aldrich), all with a minimum  
115 purity of 99 %. Buffer (0.02 M, pH 7.4) consisted of dipotassium hydrogen phosphate (> 98  
116 %, Fisher Scientific) and monopotassium hydrogen phosphate (> 99 %, Fisher Scientific)  
117 with 0.1 M sodium chloride (> 99 % Sigma Aldrich).

118 The biosurfactant extract was obtained from corn steep liquor (CSL) provided by Santa Cruz  
119 Biotechnology (Lot L1813), using chloroform stabilised with amilene (150 ppm) as organic  
120 solvent (Scharlab).

### 121 **Methods**

#### 122 *Biosurfactant extraction from corn steep liquor*

123 For obtaining the biosurfactant, CSL with a solid content of 50 % was subjected to an  
124 extraction process following the protocol established by Vecino *et al.*, [32]. For that, CSL  
125 was diluted in distilled water up to 50 mg/mL. Then, 250 mL of this solution was extracted  
126 with chloroform at 56 °C for 1 hour with a CSL:chloroform ratio 2:1 (v/v), in a KS 4000 ic  
127 control shaker (IKA, Germany). Finally, the chloroform-CSL mixture was decanted for 12  
128 hours. Once the biosurfactant was extracted, the organic solvent was eliminated by vacuum  
129 distillation obtaining an oily biosurfactant extract.

#### 130 *Physical characterisation of biosurfactant extract*

131 The surfactant activity of extract from CSL was measured using the Wilhelmy plate method  
132 and a tensiometer K20 (Kruss). For that, the biosurfactant was dissolved in water at  
133 concentrations from 0.01 to 1 mg/mL (the concentrations prepared were 0.01; 0.02; 0.05; 0.1;

134 0.125; 0.166; 0.2; 0.25; 0.5 and 1 mg/mL), in order to obtain its critical micellar  
135 concentration (CMC), with all measurements carried out in triplicate.

136 The pH of biosurfactant was measured using a calibrated pH meter Basic 20 (Crison) and its  
137 ionic charge was determined using ion exchange resins following the established protocol  
138 [33]. The resins used for studying the ionic charge of the biosurfactant were IR 120 (cationic  
139 exchange resin) and IRA 400 (anionic exchange resin). For these measurements 10 mL of  
140 biosurfactant was dissolved at concentrations of 1 mg/mL in distilled water and were placed  
141 in contact with 1 g of resins, observing changes in the surface tension of water after 30 min.  
142 As surface tension is directly related to the amount of biosurfactant entrapped by the resin,  
143 this parameter allowed determination of the presence (or absence) of biosurfactant in the  
144 remaining solution.

#### 145 *Chemical characterisation of biosurfactant extract*

146 The fatty acid composition of the biosurfactant was analysed using gas chromatography  
147 coupled to a mass spectrometer (CG-MS, Bruker Scion 451-GC) and following ISO-12966-  
148 3:2009. 10 mg of sample was diluted in 500  $\mu$ L of tert-butyl methyl ether (TBME), and 250  
149  $\mu$ L of trimethylsulfonium hydroxide (TMSH). A volume of 1  $\mu$ L of the sample was injected  
150 in split less mode, and the separation of fatty acid methyl esters (FAMES) was carried out.  
151 The column used was a DB-WAX (30 m x 0.25 mm i.d. x 0.25  $\mu$ L film thickness), heated to  
152 250  $^{\circ}$ C at a rate of 4  $^{\circ}$ C/min. The carrier gas was helium, with a flow rate of 1 mL/min. A  
153 temperature of 250  $^{\circ}$ C was set for the injector inlet and the transfer line of the detector.

154 Finally, a mass selective detector was used for mass spectra acquisition, over an m/z range of  
155 50-400, and under electron impact ionisation at a voltage of 70 eV. FAMES were identified  
156 by comparison of retention time and mass spectra of a FAME standard mix (Supelco 37  
157 Component FAME Mix: 10 mg mL of the FAME reference standard mix in methylene  
158 chloride, Sigma-Aldrich). This standard mix includes the fatty acid methyl esters reflected in  
159 Table 1. The software employed was MS Data Review (Version 8.1).

160

161 **Table 1: Composition of Supelco 37 FAME Standard Mix.**

Compound	Concentration (wt %)
<i>cis</i> -13,16-docosadienoic acid methyl ester	2
<i>cis</i> -4,7,10,13,16,19-docosahexaenoic acid methyl ester	2
<i>cis</i> -11,14-Eicosadienoic acid methyl ester	2
<i>cis</i> -5,8,11,14,17-Eicosapentaenoic acid methyl ester	2

<i>cis</i> -8,11,14-Eicosatrienoic acid methyl ester	2
<i>cis</i> -11,14,17-Eicosatrienoic acid methyl ester	2
<i>cis</i> -11-Eicosenoic acid methyl ester	2
Methyl <i>cis</i> -10-heptadecenoate	2
Methyl hexanoate	4
Methyl $\gamma$ -linolenate	2
Methyl arachidate	4
Methyl arachidonate	2
Methyl behenate	4
Methyl behenate	4
Methyl decanoate	4
Methyl dodecanoate	4
Methyl elaidate	2
Methyl erucate	2
Methyl heneicosanoate	2
Methyl heptadecanoate	2
Methyl linoleate	2
Methyl linolelaidate	2
Methyl linolenate	2
Methyl myristate	4
Methyl myristoleate	2
Methyl oleate	4
Methyl octanoate	4
Methyl palmitate	6
Methyl palmitoleate	2
Methyl pentadecanoate	2
Methyl <i>cis</i> -10-pentadecenoate	2
Methyl stearate	4
Methyl tricosanoate	2
Methyl tetracosanoate	4
Methyl tridecanoate	2
Methyl undecanoate	2

162

163 The functional groups of the biosurfactant were analysed by Fourier-transform infrared  
164 spectroscopy (FTIR). For that, pellets containing 1 mg of biosurfactant and 10 mg of  
165 potassium bromide were prepared. Infrared absorption analysis was carried out with a  
166 Nicolet 6700 FTIR system (Thermo Scientific) from 400 to 4000  $\text{cm}^{-1}$ , with a spectral  
167 resolution of 4  $\text{cm}^{-1}$ .

#### 168 *Permeation experiments*

169 PDMS membrane was soaked in phosphate buffer solution for 30 minutes prior to being  
170 mounted in the flow-through diffusion cells (PermeGear Inc., USA). After assembly the cells  
171 were placed on a cell warmer, maintained at 32 °C. 0.8 mL of the donor solution containing  
172 model compound and biosurfactant (except in the control, which contained only model  
173 compound) was added to the cell. In all experiments, saturated drug solutions were prepared  
174 whereby the resultant concentration of the model compounds in the donor solution was  
175 between 1.2 and 31.9 mg/mL with biosurfactant extract present at concentrations of 0.005  
176 mg/mL or 0.500 mg/mL. Phosphate buffer saline was pumped through the cells at  $\leq 5.0$   
177 mL/h. Samples were collected by means of a fraction collector every 45 minutes for a total of  
178 6 hours. Quantification was undertaken using UV spectroscopy (Agilent Cary 60 fitted with a  
179 Cary single cell Peltier) with the sample compartment maintained at 35 °C at the determined  
180  $\lambda_{\text{max}}$  for each compound. All experiments were conducted in triplicate with the mean value  
181 shown and standard deviation based error limits. All flow-through cells used in this study had  
182 a diffusion area of 0.554  $\text{cm}^2$ .

183

## 184 **Results & Discussion**

### 185 *Characterisation of biosurfactant extract*

186 The industrial applications of biosurfactants will depend on their properties, including their  
187 composition, their ionic charge, CMC, and ability to form micelles at low concentrations. For  
188 example, those biosurfactants with lower CMCs will produce micelles at a comparatively low  
189 concentration which is favourable from an industrial point of view. The biosurfactant under  
190 evaluation was found to have a CMC of 0.1198 mg/mL, which is very low in comparison  
191 with other biosurfactants reported in literature. For instance, researchers have reported that a  
192 biosurfactant produced by *Lactococcus lactis* exhibits a CMC of 14 mg/mL [34], whereas  
193 Madhu and Prapulla [35] reported that a biosurfactant produced by *Lactobacillus plantarum*

194 has a CMC of 6 mg/mL. Biosurfactants produced by lactic acid bacteria are of particular  
195 interest for comparative analysis with the biosurfactant under evaluation in this work because  
196 lactic acid bacteria are also known to be involved during the steeping process of corn.

197 Another important characteristic of biosurfactants is their ionic charge. Surfactants are  
198 amphipathic molecules consisting of hydrophobic (oil soluble) and hydrophilic (water  
199 soluble) moieties in one molecule. According to their charge, surfactants can be classified as  
200 anionic, cationic, non-ionic or amphoteric [36]. The biosurfactant under evaluation in this  
201 work was found to be amphoteric as it was entrapped by anionic and cationic resins. More  
202 specifically, IRA400 was able to entrap 75 % of the biosurfactant present in the solution,  
203 whereas IR120 entrapped 62 % of biosurfactant. These results demonstrate the amphoteric  
204 nature of this biosurfactant, which is in concordance with data previously reported [33].  
205 Amphoteric surfactants are ideal excipients, widely used in personal care products, as they  
206 tend to be less irritating to skin and eyes, have high biological compatibility and low toxicity  
207 in comparison with other types of surfactants [37]. A summary of the properties of the  
208 biosurfactant extracted for this study is shown in Table 2.

209 **Table 2:** Physical properties of the biosurfactant extract used in this work.

Critical Micellar Concentration (mg/mL)	0.1198 ( $\pm$ 0.026)
Minimum Surface Tension (mN/m)	41.8 ( $\pm$ 0.4)
pH	4.5
Adsorption on IRA (400)	positive
Adsorption on IR 120	positive

210 Related to the fatty acid composition, FAME analysis confirmed that fatty acids represented  
211 almost 43 % of the biosurfactant extract. These fatty acids contained 16 and 18 C units, such  
212 as palmitic, stearic, oleic, and linolelaidic acids, which represented 2 %, 7 %, 12 % and 22 %  
213 of the biosurfactant extract, respectively. These results confirm that this extract has a  
214 significant lipophilic character, as seen previously [33, 38]. As a result of the lipidic nature of  
215 this biosurfactant, it is proposed that it could improve the permeation of drugs through the  
216 skin. This theory is based upon the knowledge that the stratum corneum of skin is composed  
217 of lipidic compounds such as cholesterol and similar fatty acids to those found in this  
218 biosurfactant extract [39].

219 FTIR analysis of the biosurfactant extract (Supplementary Figure S1) displayed similar  
220 absorption bands to those obtained in previous work, demonstrating that the production of




221 this bisurfactant extract in corn steep liquor is regular and homogeneous [40]. The FTIR  
222 spectrum presented strong absorption bands between 3000  $\text{cm}^{-1}$  and 2700  $\text{cm}^{-1}$ , indicating the  
223 presence of carboxylic acids present in fatty acid esters and proteins, along with an  
224 absorption band at  $\sim 1700 \text{ cm}^{-1}$  indicative of C=O stretch. Absorption bands between 1500  
225  $\text{cm}^{-1}$  and 1300  $\text{cm}^{-1}$  are indicative of symmetric and asymmetric N-O stretch, present in  
226 amino acids.

### 227 *Permeation properties*

228 It should firstly be noted that as the amount permeated varied (depending upon solubility in  
229 the modified buffer solution), all comparative analysis was undertaken by comparing the  
230 percentage change in amount rather than the mass permeated per  $\text{cm}^2$ . For five of the ten  
231 compounds analysed, the presence of the biosurfactant significantly increased the cumulative  
232 amount of compound permeated after six hours, compared with drug alone. The increase in  
233 cumulative permeation did appear to vary depending upon the compound under investigation,  
234 ranging from a maximum increase for benzoic acid of 47 % (Figure 1) through to only a 15 %  
235 maximum increase for salicylic acid. The increase in amount permeated also appeared to be  
236 dependent upon the amount of biosurfactant present, as the addition of 0.500 mg/mL had a  
237 more profound effect on permeation compared with the addition of 0.005 mg/mL  
238 biosurfactant. For lidocaine, the presence of 0.005 mg/mL biosurfactant had no effect on  
239 permeation, and interestingly, for salicylic acid the lower biosurfactant concentration  
240 increased permeation to a greater extent than that for the higher concentration solution. This  
241 could be explained by changes produced in the micelle size, due to an increase in the number  
242 of aggregated biosurfactant molecules. For example, Sanchez et al., [41] have reported the  
243 formation of larger aggregates at concentrations above the CMC for dirhamnolipid produced  
244 by *Pseudomonas aeruginosa*. Despite the fact that the maximum concentration of  
245 biosurfactant employed was more than 5 times lower than the CMC, Malcher and Gzyl-  
246 Malcher [42] have also observed that salicylate ions facilitate the formation of polymer-  
247 micelle aggregates by screening the electrostatic repulsions between the charge surfactant  
248 head groups. Thus, in this case, salicylic acid contributed to the formation of aggregates

249 through a synergistic effect to a much greater extent than other compounds.



250

251 Figure 1: Cumulative amount permeated over six hours for benzoic acid in buffer (■), in the  
 252 presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD.


253 The cumulative amount percentage increases in permeation for the five compounds (where an  
 254 increase was observed) are summarised in Table 3.

255 Table 3: Cumulative amount percentage increase after six hours for the five compounds that  
 256 displayed an increase in permeation in the presence of biosurfactant.

Compound	% increase in cumulative permeation after six hours in the presence of 0.005 mg/mL biosurfactant	% increase in cumulative permeation after six hours in the presence of 0.500 mg/mL biosurfactant
Benzocaine	23 (± 1 %)	37 (± 2 %)
Benzoic Acid	31 (± 5 %)	47 (± 1 %)
Caffeine	17 (± 6 %)	25 (± 7 %)
Lidocaine	-6 (± 1 %)	24 (± 7 %)
Salicylic Acid	43 (± 6 %)	15 (± 4 %)


257 For one of the ten compounds analysed, namely benzotriazole, the presence of the  
 258 biosurfactant had no significant effect on the cumulative amount of compound permeated  
 259 after six hours compared with compound alone (Figure 2). This compound is known to self-

260 assemble in aqueous solution to form aggregated structures [43] which may have affected the  
261 permeation process.



262  
263 Figure 2: Cumulative amount permeated over six hours for benzotriazole in buffer (■), in the  
264 presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD.

265 For the remaining four of the ten compounds analysed the presence of the biosurfactant  
266 significantly decreased the cumulative amount of compound permeated after six hours  
267 compared with compound alone. The decrease in cumulative permeation once again, did  
268 appear to vary depending upon the compound under investigation ranging from a maximum  
269 decrease for procaine of 36 % (Figure 3), through to only a 13 % maximum decrease for  
270 ibuprofen. Furthermore, the decrease in amount permeated appeared to be less dependent  
271 upon the amount of surfactant present (compared with the compounds where an increase in  
272 permeation was observed), whereby the addition of 0.500 mg/mL only decreased permeation  
273 for one of the compounds (indomethacin) compared with the addition of 0.005 mg/mL  
274 biosurfactant.



275

276 Figure 3: Cumulative amount permeated over six hours for procaine in buffer (■), in the  
 277 presence of 0.005 mg/mL surfactant (●) and 0.500 mg/mL surfactant (▲), n = 3 and ± = SD.

278

279 The cumulative amount percentage decreases in permeation for the four compounds (where a  
 280 decrease was observed) are summarised in Table 4.

281

282 Table 4: Cumulative amount percentage decrease after six hours for the four compounds that  
 283 displayed a decrease in permeation in the presence of biosurfactant.

Compound	% decrease in cumulative permeation after six hours in the presence of 0.005 mg/mL biosurfactant	% decrease in cumulative permeation after six hours in the presence of 0.500 mg/mL biosurfactant
Ibuprofen	23 (± 2 %)	13 (± 1%)
Indomethacin	21 (± 6 %)	28 (± 3 %)
Procaine	42 (± 1 %)	36 (± 3 %)
Tetracaine	17 (± 5 %)	16 (± 4 %)

284

285 To explain why the ten compounds exhibited such variable effects in the presence of  
286 biosurfactant several physicochemical properties relating to the compounds were considered,  
287 including lipophilicity, degree of ionisation at the experimental pH, pKa, solubility, polar  
288 surface area and molecular mass. For example, it is interesting to note that procaine has a  
289 similar chemical structure to lidocaine with the minor difference being an amine and ester  
290 group on the former and an amide on the latter. This does result in procaine being less  
291 lipophilic than lidocaine and assuming the two drugs each bind to the micelle through  
292 electrostatic attractions, it may be that procaine has a greater preference to remain in the  
293 aqueous phase, rather than being incorporated within micelles and is therefore not  
294 encouraged to permeate. However, lipophilicity was deemed not to be a determining factor as  
295 to whether a compound experienced an increase or decrease in permeation. For example, a  
296 similar decrease in permeation was observed for indomethacin and procaine at the higher  
297 biosurfactant concentration, yet the two compounds have significantly different lipophilicities  
298 (calculated using Advanced Chemistry Development, Inc. (ACD/Labs) to be 4.3 and 3.1  
299 respectively).

300 After analysing all of these factors it was found that the primary factor dictating permeation  
301 was the relative molecular mass of the compound. For the five compounds that experienced  
302 an increase in permeation in the presence of surfactant, the relative molecular mass was  
303 below 200 whereas for the four that experienced a decrease in permeation the relative  
304 molecular mass was above 200. However, there was one exception to this correlation, namely  
305 lidocaine, with a relative molecular mass of 234 and a maximum increase in permeation of 24  
306 %. This anomaly may be a consequence of the amphiphilic nature of the drug allowing it to  
307 interact to a greater extent than anticipated with the biosurfactant. It is theorised that in  
308 general, a strong interaction was possible between a compound and the biosurfactant if the  
309 compound was relatively small (as indicated by a comparatively small relative molecular  
310 mass) and it is this interaction that helps encourage permeation to occur. In contrast, for the  
311 four compounds with comparatively high molecular masses, i.e. > 200, the compound-  
312 biosurfactant interaction either did not occur or resulted in a large, complex structure that  
313 struggled to permeate the silicone membrane. This theory fits well with that previously  
314 published in literature where the correlation between reduced diffusion with increasing  
315 penetrant size is well documented [44]. Overall, the findings presented in this work indicate  
316 that there is potential for the application of biosurfactants within formulations as an aid to  
317 modify transdermal permeation and that this effect can be controlled by the choice of  
318 compound selected.

319

## 320 **Conclusion**

321 In summary, the cumulative amount of permeation for ten compounds through silicone  
322 membrane in the absence and presence of a naturally occurring biosurfactant was analysed.  
323 Overall, the effect on permeation appeared to vary between the compounds, increasing  
324 permeation in some cases yet decreasing permeation in others, possibly linked to the  
325 compounds relative molecular mass as a reflection of molecular size. It would appear that  
326 those with a comparatively small mass are able to permeate more easily and to a greater  
327 extent, possibly through favourable compound-biosurfactant interactions, whereas the reverse  
328 scenario is true for compounds of a high molecular mass in that permeation is retarded.  
329 These findings are of interest for those considering the incorporation of biosurfactants in  
330 pharmaceutical, cosmetic or household products. There are many reasons why biosurfactants  
331 could be used within formulations, for example their low toxicity, ability to biodegrade and  
332 biocompatibility. However, it should also be considered that they can be more complex to  
333 obtain in a pure form, with variable composition and expensive to extract on a large scale.  
334 Overall though, the advantages offered by the inclusion of biosurfactants are significant and it  
335 is anticipated that more and more biosurfactant-based products will appear in future years.

336

## 337 **Acknowledgements**

338 This project was partly financed by the Spanish Ministry of Economy and Competitiveness  
339 (MINECO) (CTM2015-68904), Xunta de Galicia (ED431B 2017/77) and the Spanish  
340 Ministry of Education, Culture and Sport (FPU15/00205), Fundación Barrié de la Maza.

341

## 342 **References**

- 343 [1] R. Marchant, I.M. Banat, **Biosurfactants: A sustainable replacement for chemical surfactants?**,  
344 **Biotechnology Letters**, **34** (2012) 1597-1605.  
345 [2] S. De, S. Malik, A. Ghosh, R. Saha, B. Saha, **A review on natural surfactants**, **RSC Advances**, **5**  
346 **(2015) 65757-65767**.  
347 [3] X. Vecino, L. Rodríguez-López, J.M. Cruz, A.B. Moldes, **Sewage Sludge Polycyclic Aromatic**  
348 **Hydrocarbon (PAH) Decontamination Technique Based on the Utilization of a Lipopeptide**  
349 **Biosurfactant Extracted from Corn Steep Liquor**, **Journal of Agricultural and Food Chemistry**, **63**  
350 **(2015) 7143-7150**.  
351 [4] I. Mnif, D. Ghribi, **Glycolipid biosurfactants: main properties and potential applications in**  
352 **agriculture and food industry**, **Journal of the Science of Food and Agriculture**, **96** (2016) 4310-4320.

- 353 [5] A.L. Prieto, L.R. López, M.R. Fontán, A.B. Moldes, J.M. Cruz, Effect of biosurfactant extract  
354 obtained from the corn-milling industry on probiotic bacteria in drinkable yogurt, *Journal of the*  
355 *Science of Food and Agriculture*, (2018).
- 356 [6] J.M. Campos, T.L.M. Stamford, L.A. Sarubbo, Production of a bioemulsifier with potential  
357 application in the food industry, *Applied Biochemistry and Biotechnology*, 172 (2014) 3234-3252.
- 358 [7] E. Gharaei-Fathabad, Biosurfactants in pharmaceutical industry: A mini-review, *American*  
359 *Journal of Drug Discovery and Development*, 1 (2011) 58-69.
- 360 [8] A. Ferreira, X. Vecino, D. Ferreira, J.M. Cruz, A.B. Moldes, L.R. Rodrigues, Novel cosmetic  
361 formulations containing a biosurfactant from *Lactobacillus paracasei*, *Colloids and Surfaces B:*  
362 *Biointerfaces*, 155 (2017) 522-529.
- 363 [9] X. Vecino, L. Rodríguez-López, D. Ferreira, J.M. Cruz, A.B. Moldes, L.R. Rodrigues, Bioactivity of  
364 glycolipopeptide cell-bound biosurfactants against skin pathogens, *International Journal of*  
365 *Biological Macromolecules*, 109 (2018) 971-979.
- 366 [10] M. Elshikh, I. Moya-Ramírez, H. Moens, S. Roelants, W. Soetaert, R. Marchant, I.M. Banat,  
367 Rhamnolipids and lactonic sophorolipids: natural antimicrobial surfactants for oral hygiene,  
368 *Journal of Applied Microbiology*, 123 (2017) 1111-1123.
- 369 [11] P. Das, S. Mukherjee, R. Sen, Antimicrobial potential of a lipopeptide biosurfactant derived  
370 from a marine *Bacillus circulans*, *Journal of Applied Microbiology*, 104 (2008) 1675-1684.
- 371 [12] M. Rincón-Fontán, L. Rodríguez-López, X. Vecino, J.M. Cruz, A.B. Moldes, Design and  
372 characterization of greener sunscreen formulations based on mica powder and a biosurfactant  
373 extract, *Powder Technology*, 327 (2018) 442-448.
- 374 [13] M. Rincón-Fontán, L. Rodríguez-López, X. Vecino, J.M. Cruz, A.B. Moldes, Adsorption of  
375 natural surface active compounds obtained from corn on human hair, *RSC Advances*, 6 (2016)  
376 63064-63070.
- 377 [14] M. Rincón-Fontán, L. Rodríguez-López, X. Vecino, J.M. Cruz, A.B. Moldes, Influence of micelle  
378 formation on the adsorption capacity of a biosurfactant extracted from corn on dyed hair, *RSC*  
379 *Advances*, 7 (2017) 16444-16452.
- 380 [15] V.R. Sinha, M. Pal Kaur, Permeation enhancers for transdermal drug delivery, *Drug*  
381 *Development and Industrial Pharmacy*, 26 (2000) 1131-1140.
- 382 [16] Waters, L. Dennis, A. Bibi, J.C. Mitchell, Surfactant and temperature effects on paraben  
383 transport through silicone membranes, *Colloids and Surfaces B: Biointerfaces*, 108 (2013) 23-28.
- 384 [17] R.K. Sindhu, M. Chitkara, G. Kaur, P. Jaiswal, A. Kalra, I. Singh, P. Sriamornsak, Skin  
385 penetration enhancer's in transdermal drug delivery systems, *Research Journal of Pharmacy and*  
386 *Technology*, 10 (2017) 1809-1815.
- 387 [18] I. Som, K. Bhatia, M. Yasir, Status of surfactants as penetration enhancers in transdermal drug  
388 delivery, *Journal of Pharmacy and Bioallied Sciences*, 4 (2012) 2-9.
- 389 [19] B.W. Barry, Is transdermal drug delivery research still important today?, *Drug Discovery*  
390 *Today*, 6 (2001) 967-971.
- 391 [20] E.J. Gudiña, V. Rangarajan, R. Sen, L.R. Rodrigues, Potential therapeutic applications of  
392 biosurfactants, *Trends in Pharmacological Sciences*, 34 (2013) 667-675.
- 393 [21] A.C. Watkinson, M.C. Kearney, H.L. Quinn, A.J. Courtenay, R.F. Donnelly, Future of the  
394 transdermal drug delivery market - Have we barely touched the surface?, *Expert Opinion on Drug*  
395 *Delivery*, 13 (2016) 523-532.
- 396 [22] E. Abd, S.A. Yousef, M.N. Pastore, K. Telaprolu, Y.H. Mohammed, S. Namjoshi, J.E. Grice, M.S.  
397 Roberts, Skin models for the testing of transdermal drugs, *Clinical Pharmacology: Advances and*  
398 *Applications*, 8 (2016) 163-176.
- 399 [23] T.J. Franz, P.A. Lehman, S.G. Raney, Use of excised human skin to assess the bioequivalence of  
400 topical products, *Skin Pharmacology and Physiology*, 22 (2009) 276-286.
- 401 [24] A.L.M. Ruela, A.G. Perissinato, M.E.S. Lino, P.S. Mudrik, G.R. Pereira, Evaluation of skin  
402 absorption of drugs from topical and transdermal formulations, *Brazilian Journal of*  
403 *Pharmaceutical Sciences*, 52 (2016) 527-544.

404 [25] H. Todo, Transdermal permeation of drugs in various animal species, *Pharmaceutics*, 9 (2017).  
405 [26] B. Godin, E. Touitou, Transdermal skin delivery: Predictions for humans from in vivo, ex vivo  
406 and animal models, *Advanced Drug Delivery Reviews*, 59 (2007) 1152-1161.  
407 [27] L.J. Waters, Recent developments in skin mimic systems to predict transdermal  
408 permeation., *Current Pharmaceutical Design* 21 (2015) 2725 - 2732.  
409 [28] S.F. Ng, J.J. Rouse, F.D. Sanderson, G.M. Eccleston, The relevance of polymeric synthetic  
410 membranes in topical formulation assessment and drug diffusion study, *Archives of Pharmacal  
411 Research*, 35 (2012) 579-593.  
412 [29] Y. Shahzad, L.J. Waters, C. Barber, Solvent selection effects on the transport of compounds  
413 through silicone membrane, *Colloids and Surfaces A: Physicochemical and Engineering Aspects*,  
414 458 (2014) 96-100.  
415 [30] Waters, A.K.M.M.H. Bhuiyan, Ionisation effects on the permeation of pharmaceutical  
416 compounds through silicone membrane, *Colloids and Surfaces B: Biointerfaces*, 141 (2016) 553-  
417 557.  
418 [31] L. Waters, C. Finch, A.K.M.M.H. Bhuiyan, K. Hemming, J. Mitchell, Effect of plasma surface  
419 treatment of poly(dimethylsiloxane) on the permeation of pharmaceutical compounds, *Journal of  
420 Pharmaceutical Analysis*, (2017).  
421 [32] X. Vecino, L. Barbosa-Pereira, R. Devesa-Rey, J.M. Cruz, A.B. Moldes, Optimization of liquid-  
422 liquid extraction of biosurfactants from corn steep liquor, *Bioprocess and Biosystems Engineering*,  
423 38 (2015) 1629-1637.  
424 [33] L. Rodríguez-López, M. Rincón-Fontán, X. Vecino, J.M. Cruz, A. Moldes, Ionic Behavior  
425 Assessment of Surface-Active Compounds from Corn Steep Liquor by Exchange Resins, *Journal of  
426 Surfactants and Detergents*, 20 (2017) 207-217.  
427 [34] L.R. Rodrigues, J.A. Teixeira, H.C. van der Mei, R. Oliveira, Physicochemical and functional  
428 characterization of a biosurfactant produced by *Lactococcus lactis* 53, *Colloids and Surfaces B:  
429 Biointerfaces*, 49 (2006) 79-86.  
430 [35] A.N. Madhu, S.G. Prapulla, Evaluation and functional characterization of a biosurfactant  
431 produced by *Lactobacillus plantarum* CFR 2194, *Applied Biochemistry and Biotechnology*, 172  
432 (2014) 1777-1789.  
433 [36] X. Vecino, J.M. Cruz, A.B. Moldes, L.R. Rodrigues, Biosurfactants in cosmetic formulations:  
434 trends and challenges, *Critical Reviews in Biotechnology*, 37 (2017) 911-923.  
435 [37] M.J. Rosen, J.T. Kunjappu, *Surfactants and Interfacial Phenomena: Fourth Edition*, 2012.  
436 [38] L. Rodríguez-López, X. Vecino, L. Barbosa-Pereira, A.B. Moldes, J.M. Cruz, A multifunctional  
437 extract from corn steep liquor: Antioxidant and surfactant activities, *Food and Function*, 7 (2016)  
438 3724-3732.  
439 [39] D.R. Drake, K.A. Brogden, D.V. Dawson, P.W. Wertz, Thematic Review Series: Skin Lipids -  
440 Antimicrobial lipids at the skin surface, *Journal of Lipid Research*, 49 (2008) 4-11.  
441 [40] A. López-Prieto, L. Rodríguez-López, M. Rincón-Fontán, A.B. Moldes, J.M. Cruz, Effect of  
442 biosurfactant extract obtained from the corn-milling industry on probiotic bacteria in drinkable  
443 yogurt, *Journal of the Science of Food and Agriculture*, (2018).  
444 [41] M. Sánchez, F.J. Aranda, M.J. Espuny, A. Marqués, J.A. Teruel, A. Manresa, A. Ortiz,  
445 Aggregation behaviour of a dirhamnolipid biosurfactant secreted by *Pseudomonas aeruginosa* in  
446 aqueous media, *Journal of Colloid and Interface Science*, 307 (2007) 246-253.  
447 [42] T. Malcher, B. Gzyl-Malcher, Influence of polymer-surfactant aggregates on fluid flow,  
448 *Bioelectrochemistry*, 87 (2012) 42-49.  
449 [43] F. Odeh, A. Al-Bawab, Y. Li, Self-assembly behavior of benzotriazole in water, *Journal of  
450 Dispersion Science and Technology*, 31 (2010) 162-168.  
451 [44] T.C. Merkel, V.I. Bondar, K. Nagai, B.D. Freeman, I. Pinnau, Gas sorption, diffusion, and  
452 permeation in poly(dimethylsiloxane), *Journal of Polymer Science, Part B: Polymer Physics*, 38  
453 (2000) 415-434.

454



455

456


457

458

459

460 **Supplementary Information**

461



462

463 Figure S1: FTIR spectra of biosurfactant extract from CSL.

464